| Name | Title | Contact Details |
|---|
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.
Throughout our 100 plus year history, Hartig Drug has played a key role in progressive retail practices. Did you know that Hartig Drug opened the first self-service drug store in Iowa and was one of the first pharmacies to employ female pharmacists and store managers? The principles upon which A.J. Hartig founded the company, offering the best product selection and providing fanatical service to his customers, are the corner stone of our company culture today. Hartig Drug has expanded its product offerings in retail and pharmacy and has grown via the addition of many stores throughout the years. Our drug stores and pharmacies are located in communities in Northeast Iowa, Northwest Illinois, and Southwest Wisconsin. Hartig Drug operates retail stores, long-term care pharmacies, and Finley Hartig Homecare, a durable medical equipment company. Additionally, we provide pharmacy services to and for several community critical access hospitals and operate MedOne Healthcare, a pharmacy benefit management company that offers customized prescription benefit plans to businesses, prescription discount programs, prescription mail order service and specialty pharmacy services. Hartig Drug remains active in the communities in which we serve. Our employees, live, work and play in the communities in which we operate. This connection to the community is what drives us every day to provide the best possible service and products to our patients and customers. They are our neighbors. At Hartig Drug, we cherish the faith and trust patients and customers have placed in our brand and the way the Hartig name has become synonymous with value, caring associates and a wide selection of quality merchandise.
606018 F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Infrastructure, technology & strategic resources by radiologists, for radiologists.
Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.